96
Participants
Start Date
March 30, 2015
Primary Completion Date
June 2, 2017
Study Completion Date
June 2, 2017
Sham
Sham injection will be administered as a matching intravitreal injection of lampalizumab.
Lampalizumab
10 mg dose of lampalizumab administered intravitreally
Elman Retina Group, Baltimore
Wagner Macula & Retina Center, Norfolk
Char Eye Ear &Throat Assoc, Charlotte
Western Carolina Retinal Associate PA, Asheville
Carolina Retina Center PA, Columbia
Retina Cons of Charleston, Charleston
Retina Specialty Institute, Pensacola
Florida Eye Associates, Melbourne
Retina Care Specialists, Palm Beach Gardens
Florida Eye Microsurgical Inst, Boynton Beach
National Ophthalmic Research Institute, Fort Myers
Tennessee Retina PC., Nashville
Southeastern Retina Associates, Knoxville
Charles Retina Institution, Germantown
Retina Assoc of Cleveland Inc, Cleveland
Cincinnati Eye Institute, Cincinnati
Wolfe Eye Clinic, West Des Moines
Vitreoretinal Surgery, Edina
Rush University Medical Center, Chicago
The Retina Institute, St Louis
Northwest Arkansas Retina Associates, Springdale
Dean McGee Eye Institute, Oklahoma City
Retina Specialists, DeSoto
Texas Retina Associates, Dallas
W Texas Retina Consultants PA, Abilene
Colorado Retina Associates, PC, Golden
Barnet Dulaney Perkins Eye Center, Mesa
University of Arizona; Banner University Medical, Department of Opthalmology, Tucson
Eye Associates of New Mexico, Albuquerque
Sierra Eye Associates, Reno
The Retina Partners, Encino
San Diego Retina Associates, Oceanside
Loma Linda University, Loma Linda
California Retina Consultants, Santa Barbara
West Coast Retina Medical Group, San Francisco
Retinal Diagnostic Center, Campbell
Lead Sponsor
Genentech, Inc.
INDUSTRY